Treatment for Cerebral Venous Sinus Thrombosis (CVST)
Initial Management
- The American College of Chest Physicians recommends immediate anticoagulation with either intravenous unfractionated heparin (UFH) or subcutaneous low-molecular-weight heparin (LMWH) as the first-line treatment for CVST, even in patients with hemorrhagic lesions 1, 2
- Anticoagulation should be started immediately after diagnosis confirmation, regardless of the presence of intracranial hemorrhage that occurred as a consequence of CVST 3, 2
- Either intravenous unfractionated heparin or subcutaneous low-molecular-weight heparin can be used as initial treatment, with a strength of evidence based on guidelines from the American College of Chest Physicians 4, 2
- Parenteral anticoagulation therapy should be continued until the patient has stabilized clinically, as recommended by the American College of Chest Physicians 4
- All patients should be admitted to a stroke unit for close monitoring and specialized care, according to the American Heart Association/American Stroke Association 2
Evidence Supporting Anticoagulation
- Anticoagulation prevents thrombus propagation, increases recanalization chances, and reduces mortality and severe disability, with a moderate strength of evidence based on a meta-analysis of two randomized trials 3
- A small prospective cohort study of 30 children with CVST reported 3 deaths among 8 untreated children compared with no deaths among 22 treated children, providing low-quality evidence for the effectiveness of anticoagulation 5
- Anticoagulation is associated with an absolute reduction in risk of death or dependency of 13%, based on a meta-analysis of two randomized trials with a moderate strength of evidence 4
Special Considerations
- Dexamethasone may be considered in specific scenarios with significant white matter edema causing mass effect and neurological deterioration (4-8 mg/day oral or IV), with a low strength of evidence based on expert opinion 3
- Dexamethasone should not be used routinely in all CVST cases, particularly in asymptomatic patients without significant mass effect, according to the American Academy of Neurology 3
Transition to Oral Anticoagulation
- After clinical stabilization, patients should be switched from parenteral anticoagulation to oral anticoagulants, as recommended by the American College of Chest Physicians with a high strength of evidence 4, 2
- Duration of anticoagulation depends on underlying etiology, with a moderate strength of evidence based on guidelines from the American College of Chest Physicians 4, 2
Management of Complications
- Control of seizures with appropriate anticonvulsants is recommended, with a high strength of evidence based on guidelines from the American Academy of Neurology 5
- Management of elevated intracranial pressure is crucial, with a moderate strength of evidence based on expert opinion 5
Follow-up Recommendations
- Neurological and ophthalmological follow-up is recommended, especially during the first year, due to risk of visual loss from increased intracranial pressure, with a moderate strength of evidence based on guidelines from the American Heart Association/American Stroke Association 5
- Investigate underlying prothrombotic conditions, as this affects treatment duration, with a high strength of evidence based on guidelines from the American College of Chest Physicians 2
- Monitor for cognitive and neurological sequelae that may require rehabilitation and longer-term therapy, with a moderate strength of evidence based on expert opinion 5
Cautions and Pitfalls
- Discontinue oral contraceptives in affected patients, as they may increase risk of recurrent CVST, with a moderate strength of evidence based on guidelines from the American College of Obstetricians and Gynecologists 5